Avnet(AVT)

Search documents
Avnet(AVT) - 2025 Q1 - Earnings Call Transcript
2024-10-30 20:09
Avnet, Inc. (NASDAQ:AVT) Q1 2025 Earnings Conference Call October 30, 2024 12:00 PM ET Company Participants Joe Burke - Vice President, Treasurer & Investor Relations Phil Gallagher - Chief Executive Officer Ken Jacobson - Chief Financial Officer Conference Call Participants Joe Quatrochi - Wells Fargo Ruplu Bhattacharya - Bank of America Matt Sheerin - Stifel William Stein - Truist Securities Operator Welcome to the Avnet First Quarter Fiscal Year 2025 Earnings Call. I would now like to turn the floor over ...
Avnet(AVT) - 2025 Q1 - Earnings Call Presentation
2024-10-30 16:27
Avnet First Quarter Fiscal Year 2025 Financial Results /\VNET October 30, 2024 Safe Harbor Statement This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the financial condition, results of operations, and business of the Company. You can find many of these statements by looking for words like "believes," "projected", "plans," "expects," "anticipates," ...
Here's What Key Metrics Tell Us About Avnet (AVT) Q1 Earnings
ZACKS· 2024-10-30 14:35
Avnet (AVT) reported $5.6 billion in revenue for the quarter ended September 2024, representing a year-overyear decline of 11.6%. EPS of $0.92 for the same period compares to $1.61 a year ago. The reported revenue represents a surprise of +3.68% over the Zacks Consensus Estimate of $5.41 billion. With the consensus EPS estimate being $0.85, the EPS surprise was +8.24%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...
Avnet (AVT) Q1 Earnings and Revenues Surpass Estimates
ZACKS· 2024-10-30 14:10
Avnet (AVT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $1.61 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 8.24%. A quarter ago, it was expected that this distributor of electronic components would post earnings of $0.95 per share when it actually produced earnings of $1.22, delivering a surprise of 28.42%. Over the last four quar ...
Avnet(AVT) - 2025 Q1 - Quarterly Results
2024-10-30 12:05
Exhibit 99.1 Avnet Reports First Quarter 2025 Financial Results First quarter sales of $5.6 billion and diluted EPS of $0.66 Adjusted diluted EPS of $0.92 Cash flow from operations of $838 million over past four quarters PHOENIX – October 30, 2024 – Avnet, Inc. (Nasdaq: AVT) today announced results for its first quarter ended September 28, 2024. "In the first quarter, our sales and earnings exceeded the upper end of our guidance range led by a return to growth in our Asia region. We continue to focus on imp ...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswire News Room· 2024-10-10 09:01
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab). “EMA acceptance marks an important step towards making AVT03 available to patients and caregivers in Europe,” said Joseph McClellan, Chief Scientific Officer of Alvotech. “Successf ...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswire News Room· 2024-08-15 08:30
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accept ...
Avnet(AVT) - 2024 Q4 - Annual Report
2024-08-14 00:08
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4224 Avnet, Inc. (Exact name of registrant as specified in its charter) New York (State or other jurisdiction of incorporation or or ...
Avnet (AVT) Reliance on International Sales: What Investors Need to Know
ZACKS· 2024-08-12 14:21
Have you evaluated the performance of Avnet's (AVT) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this distributor of electronic components, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial he ...
Avnet (AVT) Soars 7% as Q4 Earnings and Revenues Beat Estimates
ZACKS· 2024-08-09 13:06
Avnet (AVT) shares gained nearly 7% on Thursday after the company reported better-than-expected fourth-quarter fiscal 2024 results. Its non-GAAP earnings were $1.22 per share, which came way above the Zacks Consensus Estimate of 95 cents as well as management’s guidance range of 90 cents-$1.00.However, the reported figure came 41% lower than the year-ago quarter’s non-GAAP earnings of $2.06 per share, mainly due to lower revenues.Revenues declined 15% year over year to $5.56 billion but came above the Zacks ...